Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | S100A4 | P26447 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163131 | 0.79 | MEN1 (0.38) | PDK2MEN1KMT2APOLBCDC25B | |
| SCHEMBL20323369 | 0.77 | PGR (0.44) | POLBATMKDM4EMAOAHTT | |
| SCHEMBL182096 | 0.74 | PGR (0.51) | MEN1KMT2APOLBCFTRGOPC | |
| SCHEMBL29581434 | 0.74 | PGR (0.51) | MEN1KMT2APOLBCFTRGOPC | |
| SCHEMBL23730282 | 0.73 | CFTR (0.41) | MEN1KMT2APOLBCDC25BCFTR | |
| SCHEMBL14462993 | 0.71 | S100A4 (0.42) | PDK2MEN1KMT2APOLBCDC25B | |
| SCHEMBL31671044 | 0.71 | PGR (0.42) | MEN1KMT2APOLBCFTRGOPC | |
| SCHEMBL20465583 | 0.71 | MEN1 (0.40) | PDK2MEN1KMT2APOLBHRH3 | |
| SCHEMBL16133545 | 0.69 | HRH3 (0.46) | MEN1KMT2APOLBCDC25BHRH3 | |
| SCHEMBL25201447 | 0.69 | CFTR (0.38) | PDK2MEN1KMT2APOLBCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | PDK2 2394/4885MEN1 2587/4885KMT2A 4542/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | PDK2 2394/4885MEN1 2587/4885KMT2A 4542/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | PDK2 2394/4885MEN1 2587/4885KMT2A 4542/4885 |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | PDK2 286/4885MEN1 4306/4885KMT2A 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.